ORAL GLP-1 RECEPTOR AGONIST (ORFORGLIPRON) IN THE MANAGEMENT OF OBESITY AND TYPE 2 DIABETES
Authors:
- Valéria Goulart VianaVVValéria Goulart Viana
- Enzo Goulart VianaEVEnzo Goulart Viana
- Viviane Lara LealVLViviane Lara Leal
- Gustavo Ceccatto AndradeGAGustavo Ceccatto Andrade
- Adrieli Tavares PolateAPAdrieli Tavares Polate
- Luan Caimar FuchsLFLuan Caimar Fuchs
- Maurício Cavalcante PaixãoMPMaurício Cavalcante Paixão
- André Falcão SilvaASAndré Falcão Silva
- Edermeson Roque Malheiro BrandãoEBEdermeson Roque Malheiro Brandão
- Luiz Eduardo Xavier QueirozLQLuiz Eduardo Xavier Queiroz
- Juliano Correia PortelaJPJuliano Correia Portela
- Nayeli Eliana Valles RomaniNRNayeli Eliana Valles Romani
Open Access
- 13 January 2026
- book chapter
- Published by Seven Events
- p. 43-55
Abstract
Orforglipron (LY3502970) is the first small-molecule, non-peptidic oral agonist of the glucagon-like peptide-1 (GLP-1) receptor, developed for the treatment of obesity and type 2 diabetes mellitus (T2DM). This study conducted a narrative literature review, of a descriptive and qualitative nature, aiming to compile and critically analyze scientific evidence published between 2015 and 2025 regarding the pharmacology, clinical efficacy, safety, and therapeutic applicability of this agent. The literature search was performed in PubMed, SciELO, ScienceDirect, and ClinicalTrials.gov, using controlled descriptors from the DeCS and MeSH vocabularies. A total of 19 studies, including randomized clinical trials, systematic reviews, and meta-analyses, were included. Findings demonstrated mean reductions in glycated hemoglobin (HbA1c) of 1.3–1.6% and body weight loss of 10–15%, with a favorable safety profile and mild to moderate gastrointestinal effects. Additionally, improvements were observed in cardiometabolic parameters, such as blood pressure, LDL cholesterol, and high-sensitivity C-reactive protein, suggesting a possible indirect cardioprotective effect. In conclusion, Orforglipron represents a significant innovation in metabolic therapy, combining clinical efficacy, dosing convenience, and potential cardiovascular benefit. However, its clinical consolidation will depend on the completion of ongoing phase 3 multicenter trials, which are expected to confirm its effects on long-term clinical outcomes.Keywords
This publication has 9 references indexed in Scilit:
- Pharmacokinetics, Safety, and Tolerability of Different Maintenance Dose Regimens of Mosnodenvir (JNJ‐1802) in Healthy Adult ParticipantsClinical Pharmacology in Drug Development, 2025
- Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?Expert Opinion on Pharmacotherapy, 2024
- Overweight or obesity, weight variability and the risk of retinopathy in type 1 diabetesDiabetes, Obesity and Metabolism, 2024
- Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor AgonistDiabetes Therapy, 2024
- Perinatal outcomes in women with class IV obesity compared to women in the normal or overweight body mass index categories: A population‐based cohort study in QatarObesity Science & Practice, 2023
- Glycated haemoglobin in the first year after diagnosis of type 1 diabetes is an independent risk factor for diabetic retinopathy: The IMDIAB 25 years follow‐up studyDiabetes, Obesity and Metabolism, 2023
- Transcatheter mitral valve in ring implantation: a word of caution based on histopathological workupEuropean Heart Journal, 2022
- Young Male with Intense Dyspnea, Pulmonary Infiltrate, Normal Cardiac Area and Obliteration of the Apical Portion of the Left VentricleArquivos Brasileiros de Cardiologia, 2019
- Revisão sistemática X revisão narrativaActa Paulista de Enfermagem, 2007